From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO – GYNAECO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in gynaeco
Prof Els Van Nieuwenhuysen discussed the initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer,
In this informative video, Prof Denys, engages with Prof Els Van Nieuwenhuysen on two studies presented in a Clinical Science Symposium on the surgical management of gynaecological cancers.
In this video, the MIRASOL trial (GOG 3045/ENGOT OV-55) was discussed, focusing on the evaluation of the safety and efficacy of mirvetuximab soravtansine-gynx in comparison to chemotherapy.
Prof. Hannelore Denys from UZ Ghent shared some intriguing findings from the oral abstract session on gynaecologic cancer.
In-depth stories about gynaeco
Prof Jean-François Baurain, medical oncologist at Cliniques universitaires Saint-Luc, Brussels sheds his light on the interim results of the phase 2 trial DESTINY-PanTumor-02, a tumor-agnostic study including a range of